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mouse IgG, PE-Cy5 labeled mouse IgG1 and PE labeled mouse 
IgG1. 
Results: Endothelial microparticles were significantly 
elevated in patients with HNC patients 
(CD31+/CD62E+/CD42b-: mean 1601±1479 EMP/µl; 
CD31+/CD142+/CD42b-: mean 121±135 EMP/µl) compared 
with control group (CD31+/CD62E+/CD42b-: mean 782±698 
EMP/µl; CD31+/CD142+/CD42b-: mean 688±647 EMP/µl). The 
concentration of EMP were not notably increased as result of 
RT/RCT (CD31+/CD62E+/CD42b-: mean 1629±769; 
EMP/µl;CD31+/CD142+/CD42b-: mean 1257±603 EMP/µl). 
There were no significant differences between EMP level 
before treatment, one day and 3 months after radiation 
cessation. Furthermore, there was no significant difference 
in plasma EMP level in plasma of the HNC patient undergoing 
RT alone, RT combined with chemotherapy, postoperative RT 
or postoperative RCT. 
Conclusions: The data suggest that the release of EMP is not 
a marker of ECs activation as a result of early response to 
ionizing radiation during RT/RCT in HNC patients. 
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Purpose/Objective: Prediction of the treatment response 
and overall outcome in patients is an important goal in 
radiation oncology. We aim to identify prognostic molecular 
features using gene expression profiling in gliomas. 
Materials and Methods: Data from [1] were used in this 
study. Total 152 samples including 100 glioblastomas, 21 
anaplastic astrocytomas, 19 diffuse astrocytomas and 12 
anaplastic oligodendrogliomas were selected for analysis and 
3456 genes expressed in gliomas, including 3012 unique 
sequences plus an additional 444 genes from a literature 
survey were identified. Different from using a selected 
training set in [1], the total 152 samples were included in our 
study. Progression–free survival (PFS) period was adopted as 
the clinical parameter for the treatment response. Pearson's 
linear correlation coefficients between the gene data and 
PFS record were computed for selecting the candidate genes 
for prognosis model. Hierarchical clustering was then 
computed based on the expression profile of selected genes. 
Cox proportional hazards regression was used to calculate the 
hazard ratios between different groups. 
Results: 47 genes are selected for our prognosis model and 
we have 29 genes in common with results in [1]. The 
unsupervised hierarchical clustering allows us to cluster the 
152 patients into three distinct groups based on their 
similarities measured over those selected 47 genes. The 
results of Kaplan-Meier analysis for all patients show PFS 
probabilities after 5 years are 70.2%, 0% and 25.7% for group 
1, 2 and 3 respectively. The cox proportional hazards 
regression analyses show hazard ratios 23.0, 8.8 and 0.6 for 
group 1&2, group 1&3 and group 2&3 respectively. The same 
method is also applied on the non-glioblastoma patients, 
which are able to be clustered into two groups with PFS 
probabilities after 5 years 76.0% and 0% for group 1 and 2 
respectively. The hazard ratio is calculated to be 25.5. 
 
 
 
Conclusions: In our analyses, the selected profiling results 
are useful in constructing a classification scheme and the 
unsupervised clustering method also succeeds in dividing the 
samples into good and poor prognosis groups. Compared with 
the results in [1], the good prognosis group in our result has 
higher PFS probabilities after 5 years and the unsupervised 
method is direct and easy to prevent the possible bias in the 
selection of training set in the supervised method. 
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